Recombinant Human Tumor necrosis factor ligand superfamily member 15 protein(TNFSF15) (Active)

In Stock
Code CSB-AP002341HU
Size US$3274Purchase it in Cusabio online store
(only available for customers from the US)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity >97% as determined by SDS-PAGE and HPLC.
Endotoxin Less than 1.0 EU/μg as determined by LAL method.
Activity Fully biologically active when compared to standard. The ED50 as determined by its ability to induce apoptosis using human TF-1 cells is less than 20 ng/ml, corresponding to a specific activity of >5.0x104 IU/mg.
Target Names TNFSF15
Uniprot No. O95150
Research Area Cancer
Alternative Names MGC129934; MGC129935; TL1 A; tl1; tl1a; tnf ligand related molecule 1; TNF ligand-related molecule 1; tnf superfamily ligand tl1a; TNF15_HUMAN; TNFSF15; Tumor necrosis factor (ligand) superfamily member 15; Tumor necrosis factor ligand superfamily member 15; Tumor necrosis factor ligand superfamily member 15, secreted form; Vascular endothelial cell growth inhibitor; Vascular endothelial growth inhibitor 192a; Vascular endothelial growth inhibitor; vegi; VEGI192A
Species Homo sapiens (Human)
Source E.coli
Expression Region 72-251aa
Mol. Weight 20.5 kDa
Protein Length Partial
Tag Info Tag-Free
Form Lyophilized powder
Buffer Lyophilized from a 0.2 µm filtered PBS, pH 7.4, with 0.02% Tween-20
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 5-10 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis.
Gene References into Functions
  1. TNFSF15 polymorphisms may contribute to genetic susceptibility of inflammatory bowel disease (Meta-Analysis) PMID: 29873318
  2. TL1A modulated Rheumatoid arthritis-fibroblast-like synoviocytes migration and Indian hedgehog signaling pathway using TNFR2. PMID: 29748156
  3. TL1A can induce tumor cell proliferation and promote the occurrence of colitis-associated colorectal cancer by activating Wnt/beta-catenin pathway. PMID: 29796912
  4. TNFSF15, a cytokine mainly produced by blood endothelial cells, facilitates tumor lymphangiogenesis by upregulating VEGFC expression in A549 cells. PMID: 29890027
  5. Results suggested that TNFSF15 (rs3810936 and rs4979462) SNPs may confer susceptibility to systemic lupus erythematosus (SLE) risk, which were significantly associated with the clinical phenotypes of SLE. PMID: 29803925
  6. Three alternatively spliced isoforms of VEGI, VEGI174, VEGI192 and VEGI251 have been documented. This study investigated the effects of VEGI174 and its functional domains (V7 and V8) on epithelialmesenchymal transition (EMT) in renal cell carcinoma (RCC) cells in vitro. Overexpression of VEGI174, V7 or V8 inhibited EMT. PMID: 28656288
  7. Results provide evidence that variance within TNFSF15 has the potential to affect cytokine expression across a range of tissues and thereby contribute to protection from infectious diseases such as leprosy, while increasing the risk of immune-mediated diseases including Crohn's disease and primary biliary cholangitis. PMID: 27507062
  8. single variant analysis detected a previously unreported psoriasis risk locus at TNFSF15 (rs6478108) PMID: 28973304
  9. play a role in the development of systemic sclerosis PMID: 28397078
  10. the DR3/TL1A pathway directly enhances human OC formation and resorptive activity, controlling expression and activation of CCL3 and MMP-9. PMID: 28062298
  11. the blocking of tumor necrosis factor receptor 2 (TNFR2) decreased TL1A-stimulated IL-6 production by rheumatoid arthritis fibroblast-like synoviocytes. PMID: 27081759
  12. Distinct but overlapping TNFSF15 haplotypes were demonstrated in diverticulitis patients versus healthy controls when compared with the known Crohn's risk haplotype suggesting similar but distinct genetic predispositions. This study strengthens the role for a genetic predisposition to diverticulitis that involves the TNFSF15 gene. PMID: 28624054
  13. TL1A differentially induces expression of TH17 effector cytokines IL-17, -9, and -22 and provides a potential target for therapeutic intervention in TH17-driven chronic inflammatory diseases. PMID: 27733581
  14. Our findings indicate that VEGI174 prevents progression and tumor metastasis through inhibiting epithelial-mesenchymal transition (EMT) in renal cell carcinoma (RCC) in vivo. This may provide a new approach for the treatment of RCC PMID: 28739718
  15. Data suggest that human regulatory T-lymphocytes express DR3 and demonstrate DR3/TL1A-mediated activation of signaling via MAP kinases and NFkappaB. (DR3 = death receptor 3; TL1A/TNFSF15 = tumor necrosis factor [ligand] superfamily, member 15) PMID: 28337757
  16. These results raise the possibility for involvement of TL1A/DR3/DR3-mediated mechanisms in epithelial-mesenchymal interactions and the development of inflammation-induced intestinal fibrosis in Crohn's disease. PMID: 27665176
  17. rs1250569 (ZMIZ1) and rs10114470 (TL1A) are two novel loci that indicate susceptibility to Inflammatory Bowel Disease in Han-Chinese patients. PMID: 28456797
  18. results support an idea that the genetic susceptibility of TNFSF15 to CD may be confounded, in part, by the increase of Prevotella PMID: 28197769
  19. (188)Re-NGR-VEGI has the potential as a theranostic agent. PMID: 26768609
  20. miRNA-31 can directly bind to the 3-UTR of TNFSF15, thereafter negatively regulating its expression in Caco2 cells. PMID: 27188743
  21. There were significant associations of rs3810936, rs6478108, rs6478109, rs7848647 with CD in Korean pediatric patients (P = 6.5x10(-8), P = 1.3x10(-8), P = 3.7x10(-8), P = 2.9x10(-8), respectively). PMID: 25998826
  22. Patients with mild traumatic brain injury (TBI) exhibited higher VEGI levels than those with moderate and severe TBI. PMID: 26945876
  23. Biologics beyond TNF-alpha inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders. PMID: 26810853
  24. Rs3810936 of TNFSF15 were related to the risk of ankylosing spondylitis PMID: 26823868
  25. Higher TL1A levels were associated with early stage chronic lymphocytic leukemia. PMID: 26393680
  26. TL1A-induced cell death is directly mediated through DR3. PMID: 26509650
  27. Plasma levels of TL1A were significantly higher in newly diagnosed SLE patients compared with controls, and were positively associated with SLE disease activity index. PMID: 25929716
  28. This study indicates that the HDAC inhibitor may be exploited as a therapeutic strategy modulating the soluble VEGI/DR3 pathway in osteosarcoma patients PMID: 25778932
  29. Results show that subjects with TNFSF15 -358CC genotype were at higher risks for developing gastric adenocarcinoma in the Helicobacter pylori infected group. PMID: 25251497
  30. The data indicate that TL1A may contribute to pathogenesis of inflammatory bowel diseases via local but not systemic induction of IL-17A but not IL-4, IL-13 or IFN-gamma. PMID: 26072972
  31. study has defined the increased serum and SF samples levels of TL1A and DcR3 in patients with rheumatoid arthritis (RA); findings support the hypothesis that TL1A and DcR3 may contribute to the pathogenesis of RA PMID: 25647275
  32. TNFSF15 SNPs, rs6478108 and rs4574921, may be independent genetic predictive factors for the development of stricture/non-perianal penetrating complications and perianal fistula, respectively. PMID: 24835165
  33. TL1A increases expression of CD25, LFA-1, CD134 and CD154, and induces IL-22 and GM-CSF production from effector CD4 T-cells PMID: 25148371
  34. Addition of TL1A to IL-1beta + IL-23 also augmented ILC3 proliferation PMID: 26046454
  35. This study shows an association between TNFSF15-rs3810936 and AAU and suggests that the TL1A/DR3 pathway may be implicated in the pathogenesis of this disease. PMID: 26200500
  36. associations exist between TNFSF15 gene polymorphisms and IBD (both CD and UC) in the Indian population PMID: 25501099
  37. These results suggested that TL1A could promote Th17 differentiation in rheumatoid arthritis via the activation of RORc, and this effect may be mediated by the binding of TL1A with DR3. PMID: 24832108
  38. TL1A blood levels are elevated in psoriasis patients; TL1A expression is higher in psoriatic lesions than in normal skin PMID: 25908025
  39. Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1. PMID: 25899471
  40. Soluble TL1A synergized with IL-23 to stimulate peripheral blood mononuclear cells from patients with psoriasis vulgaris to produce IL-17. PMID: 25200589
  41. This meta-analysis indicated that most of the seven TNFSF15 polymorphisms (except for rs4263839) were risk factors contributed to CD and UC susceptibility. The differences in ethnicity did not influence the risk obviously. PMID: 25028192
  42. DR3 is expressed in some interstitial vascular endothelial cells (EC) in human kidney in situ; these EC also respond to its ligand TL1A by activating NF-kappaB. PMID: 25399326
  43. Mechanisms mediating TNFSF15:DR3 contributions to pattern recognition receptor outcomes included TACE-induced TNFSF15 cleavage to soluble TNFSF15; soluble TNFSF15 then led to TRADD/FADD/MALT-1- and caspase-8-mediated autocrine IL-1 secretion. PMID: 25197060
  44. This is the first report of the association between early Crohn's disease and the TNFSF15 single nucleotide polymorphisms. PMID: 25664710
  45. Tumor-infiltrating natural killer and CD4(+) T cells under the influence of cancer cells significantly increase the production of IFNgamma, which in turn inhibits TNFSF15 expression in vascular endothelial cells. PMID: 24141405
  46. may play an important role in the pathogenesis of primary biliary cirrhosis PMID: 24016146
  47. Our data demonstrate a key role for TL1A in promoting ILC2s at mucosal barriers. PMID: 24220298
  48. Combining the genetic marker TNFSF15 with ASCA IgA increased the power of predicting stenosis/perforating phenotype in Crohn's disease patients with TNFSF15 but not with a NOD2 genetic background PMID: 24783249
  49. genetic polymorphism is associated with psoriasis and psoriatic arthritis in Hungarians PMID: 24269700
  50. attenuated S. typhimurium carrying the dual function plasmid VEGI151/survivin cannot only be specifically enriched in the tumor tissue, but also showed a synergistic antitumor effect in vivo. PMID: 23404494
  51. ADAMTS 8, CCL23, and TNFSF15 are implicated in anti-angiogenic activities PMID: 24384427
  52. The SNP rs7848647 associated with the TNFSF15 gene is associated with surgical diverticulitis. PMID: 24814505
  53. Response elements regulating TNFSF15 in primary human myeloid cells, were analyzed. PMID: 23642711
  54. increased expressiojn in gut tissue , but not in the peripheral blood, from inflammatory bowel disease patients PMID: 23250276
  55. It has been identified as a new disease susceptibility gene among Japanese. Though different from Europeans, it is indicated that a T lymphocyte differentiation route (Th1/Th17) shares a common disease developing process. [Review] PMID: 24005100
  56. VEGI, possibly via DR3, suppresses the aggressive nature of pituitary tumours and its expression level is closely linked to the invasion and destruction of the suprasellar and sella regions PMID: 24023314
  57. this suggests that VEGI functions mainly through inhibition of angiogenesis and is a negative regulator of aggressiveness during the development and progression of renal cell carcinoma . PMID: 23545578
  58. Polymorphisms in TNFSF15 were associated with irritable bowel syndrome with diarrhea. PMID: 22684480
  59. VEGI192 and VEGI174 expression is markedly decreased in clear-cell renal cell carcinoma and are linked to pathological grade and stage. PMID: 23382586
  60. TL1A is up-regulated in ankylosing spondylitis (AS), associates with disease activity and is influenced by anti-TNF treatment, suggesting that TL1A may be of pathogenic and potentially of therapeutic importance in AS patients. PMID: 23204549
  61. Circulating levels of TL1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis PMID: 23598291
  62. Two significant susceptibility loci, TNFSF15 (rs4979462) and POU2AF1 (rs4938534) (combined odds ratio [OR] = 1.56, p = 2.84 x 10(-14) for rs4979462. PMID: 23000144
  63. Protein expression of tumour necrosis factor (TNF)-like ligand 1A (TL1A) and death-domain receptor (DR)3 is upregulated in the aged bladder tissues. PMID: 22641456
  64. Vascular endothelial growth factor (VEGF) produced by cancer cells and monocyte chemotactic protein-1 (MCP-1) produced mainly by tumor-infiltrating macrophages and regulatory T cells effectively inhibits TNFSF15 production by endothelial cells. PMID: 22210436
  65. in active psoriasis, we observed abundant immunostaining for TL1A and significant upregulation of its receptors DR3 and DcR3 PMID: 21672030
  66. susceptibility gene for irritable bowel syndrome and irritable bowel syndrome constipation PMID: 21636646
  67. DcR3 may act as an inducer, and membrane-bound TL1A may act as a receptor in rheumatoid synovial fibroblasts. PMID: 21537832
  68. the TNFSF15 genotype is positively associated with isolated colonic (L2) Crohn disease. PMID: 21730793
  69. neither TNFSF15 nor IL23R variants contribute to ulcerative colitis susceptibility in Koreans PMID: 21228792
  70. Decoy Receptor 3 (DcR3)neutralizes three different TNF ligands: FasL, LIGHT, and TL1A. Crystal structure of DcR3 reported here provides a mechanistic basis for the broadened specificity required to support the decoy function of DcR3. PMID: 21300286
  71. studies for the first time establish the regulatory axis of AMPK-LITAF-TNFSF15 and also suggest that LITAF may function as a tumor suppressor PMID: 21217782
  72. Substance P- and hemokinin-1-stimulated monocytes potentiate T helper type (Th)17 cell generation in vitro through IL-1beta, IL-23, and tumor necrosis factor-like (TNF)1A expression. PMID: 21368235
  73. role in inflammatory bowel disease pathogenesis PMID: 21153332
  74. role of TNFRSF25:TNFSF15 in disease and health PMID: 21153333
  75. The TL1A/DcR3 ligand/receptor pair is upregulated in active ulcerative colitis. PMID: 20675196
  76. TL1A can regulate the inflammatory processes through modulation of the betaig-h3 expression through two separate pathways, one through PKC and PI3K and the other through ERK, which culminates at NF-kappaB activation. PMID: 20863486
  77. TL1A increased cytotoxicity of IL-12/IL-18-activated NK cells against target cells dependent on NK activation for lysis and could function in vivo as a key co-activator of NK cytotoxicity. PMID: 20349123
  78. TL1A promotes foam cell formation in human macrophages in vitro by increasing low density lipoprotein uptake, by enhancing intracellular total and esterified cholesterol levels and reducing cholesterol efflux. PMID: 20410491
  79. critically involved in the pathogenesis of rheumatoid arthritis PMID: 20125169
  80. Data suggest that lipopolysaccharide induces TL1A expression through the transcriptional activation via a NF-kappa B pathway. PMID: 19815424
  81. VEGI functions as a negative regulator of aggressiveness during development and progression of bladder cancer. PMID: 20150621
  82. Our findings suggest a role for TL1A in pro-inflammatory APC-T cell interactions PMID: 19839006
  83. Vascular endothelial growth inhibitor is an endothelial cell-specific gene and inhibitor of endothelial cell proliferation, angiogenesis, and tumor growth; mediates G1 arrest in G0/G1 cells responding to growth stimuli, and apoptosis in cell division PMID: 11739281
  84. TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis PMID: 12882979
  85. TL1A mRNA and protein expression is up-regulated in inflammatory bowel disease, particularly in involved areas of Crohn's disease (CD) in gut mucosa cell types other than endothelial, including lamina propria lymphocytes as well as tissue macrophages. PMID: 14568967
  86. Expression of TL1A and its receptor DR3 by lamina propria mononuclear cells (LPMC) could have significant influence on the severity of mucosal inflammation. PMID: 15207783
  87. TL1A and DR3 is involved in atherosclerosis via the induction of pro-inflammatory cytokines/chemokines PMID: 15760679
  88. VEGI is an endogenous inhibitor of angiogenesis PMID: 16061878
  89. Genetic variations in the TNFSF15 gene contribute to the susceptibility to inflammatory bowel diseases in Japanese and European populations. PMID: 16221758
  90. It can be concluded that VEGI72-251 is able to increase the level of human IL-2 production by the activation of T lymphocytes PMID: 16604264
  91. a significant association between TNFSF15 and Crohn's disease PMID: 16966713
  92. The induction of TL1A on APCs via specific pathway stimulation suggests a role for TL1A in Th1 responses to pathogens, and in CD. PMID: 17371957
  93. Mononuclear phagocytes are a major source of TL1A in rheumatoid arthritis (RA), as revealed by their strong TL1A expression in either synovial fluids or synovial tissue of rheumatoid factor (RF)-seropositive RA patients, but not RF-negative/RA patients. PMID: 17513783
  94. TNFSF15 is an ethnic-specific IBD susceptibility gene. Five SNPs that comprise the 2 common haplotypes were genotyped in 599 Caucasian patients with Crohn's dis, 382 Caucasian patients with ulcerative colitis, and 230 controls. PMID: 17663424
  95. TL1A forms a homotrimer with each monomer assuming a jellyroll beta-sandwich fold. The CD loop in TL1A is the longest among the TNF ligand members with known structure and the AA' loop in TL1A is the second longest after that in TRAIL. PMID: 17935696
  96. TL1A may contribute to renal inflammation and injury through DR3-mediated activation of NF-kappaB and caspase-3 PMID: 18287561
  97. Variants in TNFSF15 contribute to overall CD susceptibility in European populations, although to a lesser extent than that seen in the Japanese. PMID: 18338776
  98. TNFSF15 genotypes play an important role in the pathogenesis of Crohn's disease in Koreans. PMID: 18422820
  99. TL1A may serve as an inflammatory marker in rheumatoid arthritis. Interactions between TL1A and its receptors may be important in the pathogenesis of rheumatois arthritis. PMID: 18757243
  100. The allelic expression imbalance of TNFSF15 in peripheral blood mononuclear cells was examined to reveal the effects of the single nucleotide polymorphisms on the transcriptional activity of TNFSF15. PMID: 19124533

Show More

Hide All

Subcellular Location Membrane, Single-pass type II membrane protein, SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 15, secreted form: Secreted
Protein Families Tumor necrosis factor family
Tissue Specificity Specifically expressed in endothelial cells. Detected in monocytes, placenta, lung, liver, kidney, skeletal muscle, pancreas, spleen, prostate, small intestine and colon.
Database Links

HGNC: 11931

OMIM: 604052

KEGG: hsa:9966

STRING: 9606.ENSP00000363157

UniGene: Hs.23349

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1